Management of Type 2 Diabetes with Metformin

Rationale for Continuing Metformin

The American Diabetes Association recommends metformin as the preferred first-line therapy for type 2 diabetes, regardless of current HbA1c level, due to its efficacy, safety profile, and low cost 1.
Metformin remains effective in maintaining glycemic control, and discontinuation would likely result in HbA1c rising back toward pre-treatment levels, as the patient's HbA1c of 5.6% represents excellent control achieved while on metformin 1, 3.
The American Diabetes Association consensus explicitly recommends continuing metformin as foundational therapy even when adding other agents or adjusting treatment regimens, with a strength of evidence supporting its use 1, 3.

The American College of Physicians recommends considering deintensification when HbA1c falls below 6.5%, but this applies primarily to patients on multiple medications or intensive regimens where the risk-benefit balance shifts unfavorably, with moderate-strength evidence supporting this approach 4.
Deintensification is most appropriate when patients achieve very low HbA1c levels (<6.5%) on combination therapy including insulin or sulfonylureas, where hypoglycemia risk becomes clinically significant, based on high-quality evidence 4.

The presence of cardiovascular disease, heart failure, or chronic kidney disease (eGFR 30-60 mL/min/1.73m²) provides additional rationale for maintaining metformin beyond glycemic control alone, with strong evidence supporting its use in these populations 3.
Observational data suggest metformin use is associated with a 26% lower all-cause mortality, indicating benefits independent of glucose lowering, although the strength of this evidence is moderate 3.

Recheck HbA1c every 3-6 months to ensure glycemic control remains stable on current therapy, with high-quality evidence supporting regular monitoring 1.
Monitor for metformin-related adverse effects, particularly gastrointestinal symptoms, though these typically diminish over time and rarely necessitate discontinuation, based on moderate-strength evidence 1.
Check renal function annually (eGFR and serum creatinine), as metformin requires dose reduction if eGFR falls to 30-45 mL/min/1.73m² and should be discontinued if eGFR drops below 30 mL/min/1.73m², with strong evidence supporting regular renal function monitoring 3.

Do not discontinue metformin simply because HbA1c is "too low" in a patient on monotherapy without hypoglycemia risk, as the medication is maintaining that control, based on high-quality evidence 1.
Do not assume the patient no longer has diabetes because HbA1c normalized on treatment; type 2 diabetes is a progressive disease requiring ongoing management, with strong evidence supporting ongoing treatment 1.
Avoid targeting HbA1c below 6.5% through treatment intensification, but maintaining this level on current stable therapy is appropriate and does not require deintensification in the absence of hypoglycemia, based on moderate-strength evidence 4.